Chuck Buck developed a potential vaccine using genetically engineered yeast to combat BK polyomavirus, which can cause severe health issues in immunosuppressed patients.
2
Previous animal studies showed that an injectable BK vaccine produced lasting antibody responses, prompting a shift to an oral delivery method using live yeast.
3
Buck self-experimented with the yeast-based vaccine, documenting increased antibody levels, some reaching protective thresholds for organ transplant recipients.
4
The findings have sparked debate over vaccine safety and regulation, highlighting the risks and innovations in vaccine development.
5
The article emphasizes the unexpected intersections of medicine and innovation, showcasing the evolving landscape of health care.
